Search Results | NIH

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Search Results 2541 – 2560 of 3236

Appendix D: Review of Clinical Trials of Antiretroviral Interventions to Prevent Perinatal HIV Transmission

https://clinicalinfo.hiv.gov/guidelines/perinatal/review-clinical-trials-arv-interventions-prevent-hiv-transmission

Hepatitis B Virus/HIV Coinfection

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/coinfections-hepatitis-b-virus-hiv

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/overview-0

Special Populations: HIV and the Older Person

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/special-populations-hiv-and-older-person

Rash and Hypersensitivity Reactions

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/rash-and-hypersensitivity-reactions

Overview: Drug-Drug Interactions between Antiretrovirals and Other Drugs

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-interactions-overview

Bictegravir (BIC)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-integrase-inhibitors-bictegravir

Hepatitis C Virus

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/hepatitis-c-virus

Immunizations for Preventable Diseases in Children and Adolescents With HIV

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/immunizations-for-preventable-diseases

Stavudine (Zerit, d4T)

https://clinicalinfo.hiv.gov/guidelines/perinatal/archived-drugs-stavudine-zerit

Efavirenz (EFV)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-nnrtis-efavirenz-sustiva

Appendix C. Panel Members

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/appendix-panel-roster

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/elvitegravir

Cryptosporidiosis

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/cryptosporidiosis

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/raltegravir

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/histoplasmosis

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/chagas-disease

Drug-Drug Interactions: CCR5 Antagonist and Other Drugs

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-interactions-ccr5-antagonist

Ibalizumab-uiyk (Trogarzo, IBA)

https://clinicalinfo.hiv.gov/guidelines/perinatal/safety-toxicity-arv-agents-entry-attachment-inhibitors-ibalizumab-uiyk-trogarzo

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/darunavir